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Drug/membrane interactionsΑΤ1 receptor (AT1R) antagonists exert their antihypertensive effects by preventing the vasoconstrictive
hormone AngII to bind to the AT1 receptor. It has been proposed that these biological effects are mediated
through a two-step mechanism reaction. In the ﬁrst step, they are incorporated in the core of the lipid bilayers
and in the second step they reach the active site of the receptor through lateral diffusion. In this model,
drug/membrane interactions are key elements for the drugs achieving inhibition at the AT1 receptor. In this
work, the interactions of the prodrug candesartan cilexetil (TCV-116)with lipid bilayers are studied atmolecular
detail. Solid-state 13C-CP/MAS, 2D 1H-1H NOESY NMR spectroscopy and in silico calculations are used. TCV-116
and olmesartan, another drug which acts as an AT1R antagonist are compared for their dynamic effects in lipid
bilayers using solid-state 2H-NMR.We ﬁnd a similar localization of TCV-116 compared to other AT1 antagonists
in the intermediate polar region. In addition,we can identify speciﬁc local interactions. These interactionsmay be
associated in part with the discrete pharmacological proﬁles observed for different antagonists.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Angiotensin II (AngII) receptor blockers (ARBs) represent a class of
amphiphilic molecules that act on the renin angiotensin aldosterone
system (RAAS) by preventing the vasoconstrictive hormone AngII to
exert in a pathological state its detrimental effects on the AT1 receptor
(AT1R) [1,2]. A two-step model has been proposed to account for the
molecular basis of their antihypertensive action. More speciﬁcally, in
the ﬁrst step, they are incorporated into the lipid bilayers through the
lipid–water interface while in the second step they laterally diffuse
and reach the active site of the AT1 receptor [3–5].
The prodrug candesartan cilexetil shown in Fig. 1A (TCV-116) is
esteriﬁed at the carboxyl group of the AT1R antagonist marketed drug
candesartan (CV-11974) by the cyclohexylocarbonyloxyethyl segment30 2107274761.
iotis), tmavrom@chem.uoa.gr(Fig. 1B) [6,7]. This drug was found to possess interesting drug/
membrane interactions when compared with other AT1R antagonists
[7]. Olmesartan medoxomil (Fig. 1C) is another esteriﬁed AT1R antago-
nist prodrug and it is metabolized in the gastrointestinal tract to
olmesartan (Fig. 1D) [8,9].
The cellularmembrane is a complex system comprising of a plethora
of proteins and lipids as well as cholesterol, a molecule of paramount
biological importance (Fig. 1E) [11–16].
Phosphatidylcholines (PCs) are the most abundant lipid species
in the plasma membranes of the vascular smooth muscle cells [17]
and sarcolemma cardiac membranes but also other kinds of lipids play
a signiﬁcant role in the membrane functionality [18]. The most
frequently found PCs consist of oleic, linoleic and dipalmitoyl alkyl
chains. Fully hydrated La-dipalmitoyl-phosphatidylcholine (DPPC)
(Fig. 1F) lipids are used extensively in biophysical studies because
they spontaneously form multilamellar bilayers whose mesomorphic
changes occur in a convenient and biologically related temperature
range between 25 and 50 °C. Their dynamic and thermotropic proper-
ties have been studied using a variety of physical chemical techniques
Fig. 1. Structures of the AT1R antagonists, phosphatidylcholines and cholesterol used in our studies. L2, L4 and L7 present the sites of deuteration of DPPC. For the terminology of the
positions see [10].
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revealed also that their ARBpartition coefﬁcient in theﬂuid state resem-
bles that of natural plasma membranes of the vasculature [17,18].
Brieﬂy, the phosphatidylcholine bilayers at low temperatures occur
in the lamellar gel phase (Lβ) and at higher temperatures in the
liquid-crystalline phase (Lα). Their phase transition is accompanied by
several structural changes in the lipid molecules and trans-gauche
isomerization of the acyl conformation. The average number of gaucheconformers of the PCs alkyl chains, indicates the effective ﬂuidity. In
addition to the temperature, the effective ﬂuidity depends on the
presence of a drug molecule intercalating between the lipids.
In our previous work [7,29,30] we have left opened questions
regarding the speciﬁc lipid interactions and topographical position of
TCV-116 in lipid bilayers. In this study, solid-state high resolution 1H
NMR and 13C-CP/MAS along with stationary 2H-NMR spectra of speciﬁ-
cally deuterated DPPCwere obtained to get detailed information on the
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various phospholipid bilayers. Analogous experiments were performed
for the drug olmesartan in order to compare their speciﬁc molecular in-
teractions with the lipid bilayer. 2D 1H-1H NOESY experiments were
also performed to acquire valuable information on the interactions
within 5 Å between TCV-116 and phosphatidylcholine bilayers of
dimyristoyl and dioleolyl phosphatidylcholine bilayers (Fig. 1G, H).
This pair of molecules is chosen for comparison because in previous
studies it was found that TCV-116 and olmesartan show very beneﬁcial
drug/membrane interactions such as mild electrostatic repulsion, small
thinning effect, strong decrease of ﬂuidity and formation of drug rich
and poor domains [29,30]. In addition, olmesartan possesses carboxyl-
ate group and hydroxyl segments, which may lead the molecule in
the anchoring at a more hydrophilic environment in respect to TCV-
116 as it will be shown. Olmesartan is a newer drug and has extended
molecular features resembling that of prototype losartan, studied in
the last decade by our laboratory [3,7,31,32]. The role of the biologically
important molecule cholesterol is also sought in this study.
2. Materials and methods
2.1. Materials
Candesartan cilexetil (TCV-116)was kindly provided byMedochemie
Hellas A.E. (Pharma Cypria). Olmesartan was kindly donated by Daiichi
Sankyo Pro Pharma, Japan. DPPC and deuterated lipids were purchased
from Avanti Polar Lipids Inc. (Alabaster, AL). Cholesterol and deuterium
depleted water were purchased from Sigma Aldrich (St. Louis, MO).
2.1.1. Sample preparation
DPPC and TCV-116 stock solutions were prepared by dissolving
weighted amounts of dry lipid and TCV-116 powder in chloroform.
The drug concentrations used were x = 0.1 and 0.2 (10 mol% and
20 mol% respectively). Appropriate amounts of drug and cholesterol
were used in the ternary mixtures. The organic lipid/TCV-116, lipid/
olmesartan or lipid/TCV-116/cholesterol solutions were then evaporat-
ed at room temperature under a gentle stream of nitrogen and thereaf-
ter placed under vacuum for 12 hours in order to form a thin lipid
ﬁlm on the bottom of glass vials. The obtained mixtures were fully
hydrated (50% wt/wt deuterium depleted water) in order to achieve
multilamellar vesicles (MLVs). Approximately 20 mg of each sample
was packed tightly in 3.2 mm ZrO2 rotors.
2.2. Methods
2.2.1. Solid-state 2H NMR spectroscopy
2H solid-state NMR spectra were recorded on a Bruker Avance
600MHzWBspectrometer equippedwith a 4mmHXdouble resonance
MAS probe. Spectra were recorded without spinning the 4 mm MAS
rotor using a solid echo sequence with an echo delay of 35 μs and a
pulse length of 2.5 μs.
2.2.2. 1H and 13C CP/MAS NMR spectroscopy
All 1D 1H and 13CNMR spectra recordedwere obtained using a 4mm
MAS rotor on a Bruker Avance III 850WB spectrometer equippedwith a
Bruker 4 mm MAS HCN probe. The temperature was set to 27 °C and
10 kHz MAS was used. One pulse proton spectra were recorded using
a 3 μs 1H 90° pulse. 13C-CPMAS spectra were obtained with a 3 μs 1H
90° pulse, a 5 ms CP step using 80%–100% ramp and 67 kHz SPINAL64
1Hdecoupling during the acquisition time of 40ms [33]. Chemical shifts
were referenced indirectly via the downﬁeld signal at 40.49 ppm of
adamantane to DSS.
2.2.3. 2D 1H-1H NOESY experiments
2D 1H-1H NOESY experiments were recorded using a 3.2 mmMAS
rotor on a Bruker Avance III 850 WB spectrometer equipped with aBruker 3.2 mmMAS HCN probe. The temperature was set to 37 °C and
23 kHz MAS was used. The 1H 90° pulse was set to 2.5 μs; the best
mixing times are reported in ﬁgure captions. The experiment with
protonated DMPC was recorded using 8 scans and acquisition times
in the direct and indirect dimension of 200ms and 10ms, respective-
ly. The number of increments in the direct dimension was 464. For
deuterated DMPC 16 scans and acquisition times in the direct and
indirect dimension of 200 ms and 11 ms, respectively, were used.
The number of increments in the direct dimension was 512. The 2D
data were recorded using the TPPI method and Fourier transformed
using Gaussian Line Broading and 8192 data points in the direct
dimensions and a QSINE window function and 4096 data points in
the indirect dimensions.
2.2.4. Molecular modeling
The crystal structure of TCV-116 9 (CSD reference code: FETWEH)
was minimized using the Optimized Potential for Liquid Simulations
(OPLS-2005) force ﬁeld as it is implemented in MacroModel 9.9
(Schrodinger Suite 2012 update 2) [34] using water as a solvent. The
compound was subjected to 5000 iterations by applying the Polak–
Ribiere conjugate gradient (PRCG) general method for energy minimi-
zation. The mixed torsional/low-mode method has been applied for
the conformational search using a maximum of 1000 number of con-
formers and only the best low energy conformerswere kept. The energy
window for saving structures was set at 5.12 kcal/mol. The conforma-
tional search produced 136 different conformers. The clustering of
the conformers into families of similar structure was done using the
conformer_cluster.py script available in the Schrodinger Suite. To gener-
ate the RMSDmatrix all heavy atomswere taken into account. The aver-
age linkage method was used for the clustering. The clustering strain
was 1.003 and the best number of clusters was 18. A new group of
conformers was created containing the structures near the centroid
for each cluster. According to the 2D 1H-1H NOESY experiments of the
d54-DMPC/TCV-116 bilayers there are intramolecular interactions
between the aromatic ring A (H13-17) and cyclohexane (H33-35).
Only ﬁve representative entries are compatible with this information.
Only one of these ﬁve structures is a low energy conformer while the
other four have an energy higher by at least 5 kJ/mol. The low energy
conformer was transformed within two DMPC molecules in a topo-
graphical position supported by the solid-state 2D NOESY results
(Figs. 2 and 10).
3. Results and discussion
3.1. Solid-state 2H NMR
We have obtained spectra from drug-containing or drug-free lipid
bilayer preparations of DPPC 2H-labeled at three different sites. The
2H-labels were regioselectively placed; (1) at the 2-methylene group
of both sn-1 and sn-2 chains (1,2[2,2-2H2]-DPPC); (2) at the 4-
methylene group of the sn-1 and sn-2 chains (1,2[4,4-2Η2]-DPPC); (3)
and at the 7-methylene group of the sn-1 and sn-2 chains (1,2[7,7-
2Η2]-DPPC).
A deuteriumnucleus gives rise to a doublet in a powder or an orient-
ed sample because of the interaction between its electric quadrupole
moment and the electric ﬁeld gradient at the nuclear site. This interac-
tion is of anisotropic nature and the spectral lines have a frequency
difference of ΔνQ = ν1− ν2 = (3/4) e
2qQ
h (3cos
2θ− 1), which depends
on the angle θ between the magnetic ﬁeld and the axis of molecular
ordering. In the liquid crystalline phase, the phospholipid bilayers
have all θ values possible and the spectrum from 2H nuclei at one site
in the molecule is a “powder pattern” in which the two principal
peaks correspond to θ = 90o (perpendicular edges) and the two
shoulders to θ= 0ο (parallel edges). The separation between the two
90o-edges is deﬁned as the quadrupolar splitting (ΔνQ). At phases
below the main phase transition, the axial diffusion is intermediate or
Fig. 2. Algorithm used during the construction of Fig. 10.
Fig. 3. A) 3D representation of the 2R and 2S deuterated sites. B) (left) 2H NMR spectra
of 1,2[2,2-2H2]-DPPC bilayer preparations alone at a temperature range of 15–45 °C,
(middle) with TCV-116 (x= 0.20) and (right) with olmesartan (x= 0.20).
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does not show any sharp features. By studying the spectral shape as a
function of temperature andΔνQ changes attributed to the intercalation
of the drug, information on the dynamic properties of the lipid bilayer,
in the particular region where the 2H-label is placed, can be derived.
3.1.1. Spectra of 1,2[2,2-2H2]-DPPC preparations containing TCV-116
Fig. 3 illustrates the solid-state NMR spectra of 1,2[2,2-2H2]-DPPC bi-
layer preparations in the absence and presence of TCV-116 (x= 0.20).
In the liquid crystalline phase (45 °C), the spectrum of DPPC bilayers
shows three quadrupolar splittings 11,9 (2-S), 17,2 (2-R) and 26,2
(-CD2) kHz (Table 1) [35].
The presence of the drug results in the increase of ΔνQ values as it is
shown in Table 1 at temperatures 40 and 45 °C, where bilayers are in
the liquid crystalline phase indicating that it reduces its mobility.
At a temperature of 35 °C the DPPC bilayers with or without the
presence of TCV-116 show a superimposition of gel and liquid compo-
nents implying that lipid bilayers are in the Pβ′ state. At a temperature
range of 15–30 °C the two samples show wide spectra (ca 120 kHz)
with rounded-top peak. These spectra correspond to the gel phase
(Lβ′). Three important observations are made: (a) ΔνQ of 2-S remained
constant for the two preparations at the liquid crystalline phase; (b)
ΔνQ of 2-R and CD2 decreased with increase of the temperature in the
liquid crystalline phase; (c) TCV-116 causes an increase of ΔνQ in the
liquid crystalline state.
3.1.2. Spectra of 1,2[4,4-2H2]-DPPC preparations containing TCV-116
Fig. 4 shows the solid-state NMR spectra of 1,2[4,4-2H2]-DPPC bilay-
er preparations in the absence and presence of TCV-116 (x= 0.20).
As in the previous spectra (Fig. 3) in the temperature range of 15–
25 °C the two samples show wide spectra (ca. 120 kHz) with
rounded-top peak indicating that they are in the gel phase (Lβ′). At
30 °C the preparation containing the drug is in the Pβ′ phase as the gel
and liquid components are evident. At 35 °C the lipid bilayer without
TCV-116 is in the Pβ′ phase although with less liquid component
compared to the preparation containing TCV-116 at 30 °C. The TCV-
116 containing bilayer is already in the liquid crystalline phase at
35 °C. At 40 °C both preparations are in the liquid crystalline phase. It
is eminent from the spectra that the drug exerts more signiﬁcant action
on this site as the phase transition appears at lower temperature.As with the speciﬁc deuteration at site 2, the presence of the drug
causes an increase of ΔνQ indicating that it intercalates in this region
and makes the lipid bilayers more compact (Table 1).
Table 1
ΔνQ values of 1,2[2,2-2Η2]-DPPC, 1,2[4,4-2Η2]-DPPC and 1,2[7,7-2Η2]-DPPC bilayers alone (A) with TCV-116 (B) and olmesartan (C) at a temperature range of 40–45 °C.
Τ (°C) 2-S (kHz) 2-R (kHz) -CD2 (kHz) 1,2[4,4-2Η2] 1,2[7,7-2Η2]
A B C A B C A B C A B C A B C
40 11.9 13.6 12.5 18.1 19.4 17.9 27.5 28.2 27.0 25.8 27.1 25.5 27.2 29.3 26.8
45 11.9 13.7 12.4 17.2 18.7 17.1 26.2 27.3 25.6 24.3 25.6 24.1 25.0 27.0 25.0
Values are subjected to 1% error.
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Fig. 5 shows solid-state spectra of 1,2[7,7-2H2]-DPPC bilayer prepa-
rations containing TCV-116 (x = 0.20). The spectra at a temperature
range of 15–30 °C show that the two preparations are in the gel
phase. At 35 °C the spectrum of the drug-free 1,2[7,7-2H2]-DPPC bilayer
preparations shows clearly the co-existence of two components, the
broad gel-phase line shape and the sharp liquid crystalline Pake pattern.
The preparation containing the TCV-116 is almost in the liquid crystal-
line phase. At 40 °C and above, both preparations are in the liquid crys-
talline phase.ΔνQ values in the liquid crystalline phase are higher in the
drug containing lipid bilayers preparation (Table 1). The results show
that drug has consistent effect in the upper segment of the lipophilic
region regarding the increase ofΔνQ. Thus, its localization in this region
results in the decrease ofmembranemobility. Interestingly, the increase
ranges between 4% and 8% at all positions except at 2-S where the in-
crease was more signiﬁcant reaching 14.2%.
From the deuterated spectra it is evident that the most pronounced
effect caused by the TCV-116 is at 35 °C (Figs. 3–5 and Fig. S1). In partic-
ular, the sample 1,2[4,4-2Η2]-DPPC/TCV-116 at 35 °C (Fig. 4) is in the
liquid crystalline phase while the sample 1,2[2,2-2Η2]-DPPC/TCV-116
(Fig. 3) at the same temperature shows both gel and liquid crystalline
components. Interestingly, the sample 1,2[7,7-2Η2]-DPPC/TCV-116
(Fig. 5) is mostly in the liquid crystalline phase but still the phase tran-
sition is not completed. Thus, it appears that the TCV-116 affects the
lipid bilayer phase transition in a not predicted way, exerting its maxi-
mum effect when the deuteration takes place at 4 site of sn-2 alkyl
chain.
Generally, TCV-116 increases ΔνQ when DPPC is deuterated at 2, 4
and 7 sites meaning that when it is intercalated in the upper segment
of lipophilic region, it decreases the ﬂuidity of the lipid bilayers. These
results are in agreement with other biophysical techniques used such
as Small Angle X-ray diffraction, differential scanning calorimetry and
Raman spectroscopy [30]. In a previous study, we have shown that psy-
chotropic Δ8-tetrahydrocannabinol that anchors in the mesophase also
increases ΔνQ when the lipid bilayers are deuterated at the sameFig. 4. (left) 2H NMR spectra of 1,2[4,4-2H2]-DPPC bilayer preparations alone at a temperat
(x = 0.20).position. In contrast, the methylated analogue is embedded deeper in
lipid bilayers and does not exert ΔνQ enhancement [36].
Our obtained ΔνQ values of solid-state 2H-NMR spectra differ from
those reported in the literature for 41 °C for the used deuterated
DPPC, although sample preparations were identical [37,38]. Most likely
the observed differences can be attributed to a different temperature
calibration.
3.1.4. Comparative effects of TCV-116 with olmesartan
For comparative purposes we performed identical experiments
using olmesartan (Figs. 3–5). As it is shown, the effects of olmesartan
are distinct. At 2′-S it causes a less signiﬁcant increase of ΔνQ with
respect to TCV-116 and at 2′-R and -CD2 it causes a decrease. Thus,
this position has a bimodal effect not observed for TCV-116. The spectra
in the temperature range of 15–45 °C show that between 15 and 30 °C
the preparation containing olmesartan is in the gel phase and between
35 and 45 °C in the liquid crystalline phase. Interestingly, at 35 °C the
incorporated olmesartan in 1,2[2,2-2Η2]-DPPC bilayers triggers a larger
effect compared to TCV-116. Olmesartan causes less effect at 1,2[4,4-
2Η]-DPPC. At 30 °C the 1,2[4,4-2Η2]-DPPC/TCV-116 has more liquid
component relatively to 1,2[4,4-2Η2]-DPPC/olmesartan preparation.
Below the phase transition 1,2[4,4-2Η2]-DPPC/olmesartan bilayers are
in the gel phase and above they are in the liquid crystalline phase as
in 1,2[4,4-2Η2]-DPPC/TCV-116 bilayers. Again, olmesartan causes a
decrease in ΔνQ values in contrast to TCV-116. Thus, it appears that
the effect of olmesartan is decreased as the deuterium label is deeper
in the hydrophobic core. This is even more evident in 1,2[7,7-2Η2]-
DPPC bilayers. The spectra of 1,2[7,7-2Η2]-DPPC/olmesartan bilayers
resemble those of 1,2[7,7-2Η2]-DPPC bilayers indicating that olmesartan
has no signiﬁcant effect deeper in the hydrophobic core. This is clearly
seen in a comparison of the three preparations at 35 °C (see Figs. 3–5
and Fig. S1). 1,2[7,7-2Η2]-DPPC and 1,2[7,7-2Η2]-DPPC/olmesartan con-
tain superimposed gel and liquid components, while the 1,2[7,7-2Η2]-
DPPC/TCV-116 bilayers are almost completely in the liquid crystalline
phase.ure range of 15–40 °C, (middle) with TCV-116 (x= 0.20) and (right) with olmesartan
Fig. 5. (Left) 2H NMR spectra of 1,2[7,7-2H2]-DPPC bilayer preparations alone at a temperature range of 15–45 °C, (middle) with TCV-116 (x= 0.20) and (right) olmesartan (x= 0.20).
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detailed interactions of drugs in lipid bilayers. TCV-116 is a bulkier
molecule which affects signiﬁcantly the upper lipophilic segment.
Olmesartan restraints its action only up to 2 positions. The two AT1R
antagonists exert differential effects at the 2 position. Olmesartan exerts
bimodal action by causing increase of ΔνQ at 2-S position in contrast
with 2-R and -CD2 positions where it causes decrease. TCV-116 has a
homogeneous effect at the three sites by increasing ΔνQ. These results
are in agreement with reported logP values [37]. TCV-116 is more
lipophilic and it is expected to embed itself deeper in the bilayer core.
3.2. 1H and 13C CP/MAS NMR spectroscopy of DOPC bilayers alone, with
cholesterol and with cholesterol/TCV-116
Lipid packing is aggravated by the unsaturation due to the kinks
formed. DOPC bilayers show a phase transition at very low temperature
(Tm ≈ −22 °C) [39]. Lipid packing can inﬂuence the ﬂuidity of the
membrane and in turn the rotation and diffusion of drugs within the
membrane. More importantly, it is interesting to study the inﬂuence
of drug properties in unsaturated membrane bilayers containing
cholesterol. The stronger inﬂuence of cholesterol in saturated lipid bi-
layers versus unsaturated is already shown in the case of losartan [32].
3.2.1. 1Η NMR spectra
1H NMR spectrum of DOPC bilayers in D2O is shown in Fig. 6A. The
obtained spectra compare well with published spectra and thus the
published assignment was used; see Table 2 [10].
In Figs. 6B and Fig. S2 the 1H NMR spectra of DOPC bilayers contain-
ing 30% and 15% molar ratio of cholesterol are shown respectively, and
in Table 2 the 1H chemical shifts of the corresponding spectra and the
results by Zorin et al. [10] are reported. The spectra were consistent
with those reported in the literature (DOPC/CHOL 33%). The observed
minor deviations (less than 2%) are attributed to the different concen-
trations used. Additional peaks derived from steroidal rings A and B as
well as H18 and H19 are observed (Figs. 6Β, S2 and Table 3). Protons
of the cholesterol alkyl chain are not resolved because they are overlap-
ped with those of the alkyl chains of the phospholipid. The additional
peaks attributed to cholesterol in the two preparations are identical
and more pronounced in the bilayer containing the higher percentage
of cholesterol as expected.Figs. 6C and S2 illustrate the 1Η NMR spectra of DOPC/TCV-116
(x = 0.20) and, DOPC/TCV-116 (x = 0.10) respectively, and in
Tables 2 and 4 the chemical shifts of the two preparations are reported.
The spectra are almost identical and peaks are of similar linewidths. The
same applies and for the spectra containing DOPC/cholesterol/TCV-116
and DOPC/cholesterol.
In Table 4 the chemical shifts observed for TCV-116 in d6-DMSO are
reported [30]. The results show that all structural segments of TCV-116
are embedded in the phospholipid bilayers as additional peaks are
observed both from the aromatic region and non-aromatic regions
(H7, H11).
In Figs. 6D and S2 the 1H NMR spectra of [DOPC/CHOL (x= 0.30)]/
TCV-116 (x= 0.20) and [DOPC/CHOL (x= 0.15)]/TCV-116 (x= 0.20)
are shown. The proton chemical shifts of the two preparations are
shown in Tables 2, 3 and 4.
The spectra of the two preparations present identical peaks as it is
expected. The spectrum with increased concentration of cholesterol
gives correspondinglymore intense peaks. In these spectra, the aromat-
ic regions of TCV-116 as well as H11 are apparent. Cholesterol's peaks
attributed to Η3a, H7eq, H18, H19, H4 and H5 are also apparent. These
results lead to the conclusion that both cholesterol and TCV-116 are
incorporated into the DOPC bilayers at the same time as additional
peaks attributed to their structures are eminent in the spectra and
DOPC bilayers can accommodate both of them.
3.2.2. 13C CP/MAS spectra
Figs. 7A and 8A show the 13C CP/MAS-NMR of DOPC bilayers in D2O
at 27 °C whereas the 13C chemical shifts are shown in Table S1. The ob-
tained values are in agreement with those reported by Zorin et al. [10].
In Figs. 7Β, 8Β, S3 and S4, the 13C CP/MAS-NMR spectra of DOPC
bilayers containing 15% and 30% molar ratio cholesterol are shown. In
Tables S1 and S2 the chemical shifts of the two preparations are report-
ed. As with 1H NMR spectra the results were in agreement with those
reported in the literature [10,40] and less than 2% deviations are
observed. Additional information can be obtained by these spectra as
almost all peaks attributed to cholesterol are clearly observed.
In Figs. 7C, 8C, S3 and S4 the 13C CP/MAS-NMR spectra of DOPC/TCV-
116 (x= 0.10) and DOPC/TCV-116 (x= 0.20) are shown. Both spectra
are almost identical and only the low intense carbons aremore eminent
when the higher concentration of x = 0.20 is used. The observed
chemical shifts are shown in Tables S1 and S3. In Table S3 the chemical
Fig. 6. 1HNMRspectra of (A)DOPC, (B)DOPC/cholesterol (molar ratio 70:30), (C) DOPC/TCV-116 (molar ratio 80:20), and (D) [DOPC/cholesterol]/TCV-116 (molar ratio 80:20) obtained at
27 °C using 850 MHz Bruker spectrometer.
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Table 2
DOPC 1H chemical shifts (ppm) of the preparations (a) DOPC, (b) DOPC/cholesterol, (c) DOPC/TCV-116, and (d) DOPC/cholesterol/TCV-116 obtained at 27 °C using 850 MHz Bruker
spectrometer.
Atoms or groups DOPC/H2O DOPC/D2O Literature data
(DOPC/H2O) [10]
DOPC/cholest.
(x = 0.30)
DOPC/cholest.
(x = 0.15)
Literature
data (x = 0.33)
(H2O) [10]
DOPC/TCV-116
(x = 0.10)
DOPC/TCV-116
(x = 0.20)
[DOPC/CHOL
(x = 0.30)]/
TCV-116
(x = 0.20)
[DOPC/CHOL
(x = 0.15)]/
(x = 0.20)
Lα 4.29 4.35 4.28 4.35 4.36 4.28 4.33 4.32 4.33 4.33
Lβ 3.68 3.74 3.70 3.73 3.75 3.70 3.72 3.71 3.72 3.71
Lγ 3.24 3.30 3.26 3.29 3.31 3.26 3.28 3.27 3.28 3.27
L1′ 4.22 4.29 4.24 4.29 4.30 4.24 4.25 4.24 4.27 4.25
L2′ 5.29
L9 5.33
L10 5.30 5.38 5.29 5.36 5.38 5.31 5.36 5.35 5.36 5.36
L3′ 4.00 4.07 4.01 4.07 4.07 4.01 4.04 4.03 4.05 4.04
LCO-sn1 4.43 4.50 4.46 4.49 4.50 4.42 4.46 4.45 4.47 4.46
LCO-sn2 2.41 2.47 2.44 2.47 2.48, 2.48 2.41 2.39 2.42,
2.37
2.41, 2.36
L2 2.34,
2.31
2.40,
2.39
2.36 2.41,
2.36
2.42,
2.37
2.36 2.35,
2.31
2.33,
2.30
2.32 2.31
L3 1.60 1.66 1.63 1.66 1.67 1.61 1.61 1.59 1.62 1.61
L4-7, L12-17 1.29 1.36 1.32 1.36 1.37 1.39,
1.34,
1.30
1.34 1.33 1.35 1.34
L8/L11 2.01 2.08 2.01 2.08 2.09 2.03,
2.02
2.06 2.05 2.07 2.06
L18 0.88 0.95 0.89 0.94 0.96 0.89 0.94 0.93 0.94 0.94
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13C CP/MAS-NMR spectrum allows the conﬁrmation of 1Η NMR results.
In Figs. 7D, 8D, S3 and S4, the 13C CP/MAS NMR spectra of
[DOPC/CHOL (x = 0.30)]/TCV-116 (x = 0.20) and [DOPC/CHOL (x =
0.15)]/TCV-116 (x = 0.20) are shown. The carbon chemical shifts of
the two preparations are shown in Tables S1–S3. The results show
that almost all peaks attributed to cholesterol are observed and
many peaks originated from the aliphatic and aromatic region of
TCV-116. Accommodation of cholesterol in DPPC bilayers with other
AT1R antagonists was also reported [7,29,30].
3.3. 2D 1H-1H NOESY NMR experiments
2D 1H-1H NOESY NMR experiments were performed in order
to establish within b5 Å spatial correlations between TCV-116 andTable 3
Cholesterol's 1H Chemical shifts (ppm) for DOPC/cholesterol samples at 27 °C.
Atoms or
groups
DOPC/Cholest.
(x = 0.30)
DOPC/Cholest.
(x = 0.15)
Literature dat
(x = 0.33) [1
H3ax 3.50 (m) 3.50 3.50
H7eq 1.90 1.91 1.87
H18 0.79 0.79 0.77
H19 1.10 1.11 1.08
Table 4
1H Chemical shifts (ppm) for the preparations DOPC/TCV-116 (x = 0.10), DOPC/TCV-116
(x = 0.15)]/candesartan cilexetil and TCV-116 in d6-DMSO at 27 °C.
Atoms or
groups
DOPC/TCV-116
(x = 0.10)
DOPC/TCV-116
(x = 0.20)
TCV
in D
Hcil11 5.68, 5.62 5.66, 5.60 5.50
Hcil7, 7.18, 7.08, 7.03, 6.93 7.17, 7.07, 7.03, 6.93 6.78
Hcil13/17, 6.89
Hcil14/16 6.99
Hcil19/28 7.50 7.49 7.46
Hcil20/22 7.68, 7.57, 7.55 7.66, 7.57, 7.54 7.63
Hcil21 7.68, 7.57, 7.55 7.66, 7.57, 7.54 7.54
Hcil26 7.85, 7.76 7.84, 7.75 7.73
Hcil27 7.37 7.36 7.21dimyristoylphosphatidylcholine (DMPC). Table S4 shows the
1H NMR assignment and Fig. S5 shows the corresponding 1H NMR
spectrum. From the spatial correlations observed, of special interest
were those between the aromatic ring and the different segments
of DMPC (Figs. 9 and S6).
Since there was an overlapping between the different segments of
DMPC and TCV-116, another 2D NOESY experiment was performed
using d54-DMPC (Figs. 9 and S7). Thus, with the combination of the
two experiments we were able to derive information on the spatial
correlations between TCV-116 and DMPC. Fig. 9A shows that all aromatic
protons of TCV-116 are in spatial proximity with the L4–13 segment
of DMPC in an excellent agreement with solid-state 2H-NMR results.
In addition, NOE correlations between the cyclohexane ringwith glycerol
backbone region and head-group clearly show that cyclohexane ring is
pointing toward the head-group region (see Fig S8).a
0,40]
[DOPC/Cholest (x = 0.30)]/
TCV-116 (x = 0.20)
[DOPC/Cholest (x = 0.15)]/
TCV-116 (x = 0.20)
3.48 3.48
1.90 1.91
0.77 0.76
1.07 1.06
(x = 0.20), [DOPC]/cholesterol (x = 0.30)]/candesartan cilexetil, [DOPC]/cholesterol
-116
MSO
[DOPC/Cholest. (x = 0.30)]/
TCV-116 (x = 0.20)
[DOPC/Cholest (x = 0.15)]/
TCV-116 (x = 0.20)
(s) 5.70, 5.61 5.68, 5.59
(m) 7.17, 7.08, 7.04, 6.93 7.17, 7.07, 7.03, 6.93
(d)
(d)
(dd) 7.50 7.55, 7.50
(td) 7.64, 7.56 7.55, 7.50
(t) 7.64, 7.56 7.55, 7.50
(d) 7.93, 7.80 7.84, 7.75
(t) 7.36 7.36
Fig. 7. 13C CP/MAS NMR spectra of (A) DOPC, (B) DOPC/cholesterol (molar ratio 70:30),
(C) DOPC/TCV-116 (molar ratio 80:20), and (D) [DOPC/cholesterol]/TCV-116 (molar
ratio 80:20) obtained at 27 °C using 850 MHz Bruker spectrometer.
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additional information. Since the alkyl chain was deuterated, it was
possible to observe the intra-molecular interactions between the
aromatic ring A (H13–17) with cyclohexane (H33–35). Such interac-
tions are absent in the crystallographic structure of TCV-116 [41].
From the reported conformers of our previous work [30] using MD
calculations, only model B can be compatible with this information. In
model C, the cyclohexane ring is pointing toward the aromatic ring
and such conformation is not observed in the 2D 1H-1H NOESY NMR
spectrum. These inter- and intra-molecular interactions, which areobserved with the combination of the two experiments, provide a
more precise model regarding the topographical position of TCV-116
and its molecular interactions with DMPC segments that complement
our previous MD calculations.
4. Conclusions
In this article the comparative dynamic effects of TCV-116 and
olmesartan are sought. As it is reported [37,42] TCV-116 has higher
lipophilicity with respect to olmesartan. Thus, it is expected that TCV-
116 will be embedded deeper in the hydrophobic core and exerts
more perturbation on this region compared to olmesartan. Indeed,
TCV-116 ﬂuidizes more the lipid bilayers and exerts more pronounced
effect when DPPC is deuterated at sites 4 and 7. In contrast, when the
DPPC is deuterated at site 2, olmesartan exerts a more signiﬁcant effect
although both molecules perturb the lipid bilayers at this speciﬁc
region.
It is evident that TCV-116 exerts stronger hydrophobic interactions
than olmesartan, although both of them are localized in the mesophase
region where they can maximize their amphipathic interactions. Their
differences in lipophilicity and speciﬁc drug/membrane interactions
may account for their distinct pharmacological proﬁle.
In previous publications it was stated that olmesartan and losartan
are most probably located at the head-group region and upper segment
of the membranes [29,31]. Our obtained results support this view for
olmesartan. In addition, it was stated that TCV-116 prefers to locate
itself in the interior of DPPC [43]. Both statements are proved true. The
present applied techniques conﬁrmed unequivocally the above results
and provide complementary information. The presented 2D NOESY
experiments allow also to differentiate between reported models B
and C obtained through MD experiments and reported elsewhere [30].
Our results favor model B and amore quantitative model is constructed
which shows precisely the topography of TCV-116 and olmesartan
between two adjacent DMPC phospholipids (Fig. 10).
Additionally, the effects of TCV-116 in the unsaturated DOPC bilay-
ers in the presence and absence of cholesterol are studied in an attempt
to complement our previous reported data. From Table 2 it can be in-
ferred that 1H chemical shift differences between the DOPC samples
containing either cholesterol or TCV-116 or both are small. This
shows that lipid bilayers do not experience drastic changes in terms
of their structure when cholesterol is substituted by TCV-116. The
fact that drug signals are observed in 13C-CP/MAS spectra of DOPC/cho-
lesterol indicates that they are immobilized by binding to the mem-
brane. If cholesterol was squeezing TCV-116 in the aqueous
environment theywould not be visible in the CP spectra. The same pic-
ture is emerging with 13C chemical shift differences. No signiﬁcant
chemical shift differences (b0.1 ppm) were observed, which would
be expected in the case of signiﬁcant structural changes or a change
in the hydrogen bonding network as we have observed in other
drugs such as the cannabinoids [42]. Interestingly, DOPC bilayers
showed constantly lower chemical shift values relatively to the rest
of the preparations. Cholesterol appears to modify and compete with
the properties of AT1R antagonists, but both cholesterol and AT1R an-
tagonists conserve the structural properties of the lipid bilayers in
order to easily accommodate them.
Abbreviations
AT1R angiotensin II type 1 receptor
CP/MAS cross polarization magic angle spinning
DMPC dimyristoyl phosphatidyl choline
DOPC dioleoyl phosphatidyl choline
DPPC dipalmitoyl phosphatidyl choline
OPLS Optimized Potential for Liquid Simulations
PRCG Polak–Ribiere conjugate gradient
RAS renin angiotensin system
TCV-116 -candesartan cilexetil
Fig. 8. Expanded regions of the 13C CP/MAS NMR spectra of (A) DOPC, (B) DOPC/cholesterol (molar ratio 70:30), (C) DOPC/TCV-116 (molar ratio 80:20) (D) [DOPC/cholesterol]/TCV-116 (molar ratio 80:20) obtained at 27 °C using 850 MHz Bruker
spectrometer.
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Fig. 9. Correlations between the aromatic ring and alkyl chain of DMPC bilayers: (A) not
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deuterated and (B) deuterated using a 2D 1H-1H NOESY NMR experiment obtained at
37 °C at 850 MHz. The mixing time was 150 ms and 200 ms in (A) and (B), respectively.Fig. 10. Localization of TCV-116 (left) and olmesartan (right) between two adjacentDMPC
phospholipids.References
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